background
corona
viru
diseas
due
novel
coronaviru
emerg
wuhan
citi
rapidli
spread
throughout
china
aim
compar
arbidol
lopinavirritonavir
lpvr
treatment
patient
lpvr
method
retrospect
cohort
studi
includ
adult
age
laboratoryconfirm
without
invas
ventil
diagnos
jan
feb
patient
diagnos
jan
given
oral
arbidol
lpvr
combin
group
oral
lpvr
monotherapi
group
day
primari
endpoint
neg
convers
rate
coronaviru
date
diagnosi
assess
whether
pneumonia
progress
improv
chest
ct
result
analyz
patient
receiv
oral
arbidol
lpvr
combin
group
oral
lpvr
monotherapi
group
initi
diagnosi
baselin
clinic
laboratori
chest
ct
characterist
similar
group
could
detect
patient
nasopharyng
specimen
combin
group
seven
day
compar
monotherapi
group
p
day
respect
could
detect
p
chest
ct
scan
improv
patient
combin
group
seven
day
compar
monotherapi
group
p
conclus
patient
appar
favor
clinic
respons
arbidol
lpvr
support
lpvr
sinc
first
describ
decemb
seventi
thousand
case
corona
viru
diseas
confirm
beyond
two
thousand
patient
fatal
far
infect
keep
spread
export
case
confirm
provinc
china
countri
indic
diseas
seriou
threat
global
health
manag
patient
consist
combin
support
measur
antimicrobi
therapi
associ
bacteri
viral
infect
strict
implement
appropri
infect
control
precaut
number
diseas
still
multipli
effect
antivir
treatment
therefor
requir
urgent
hypothes
immunopatholog
respons
trigger
viral
antigen
strateg
treatment
therefor
stop
viral
replic
begin
peak
viral
load
subsequ
immunopatholog
damag
minimis
report
find
result
outcom
patient
compar
combin
arbidol
lopinavirritonavir
lpvr
lpvr
placebocontrol
studi
difficult
perform
epidem
lifethreaten
condit
singlecent
retrospect
cohort
studi
includ
individu
diagnos
laboratoryconfirm
http
serum
bilirubin
lung
total
sever
score
test
posit
stool
data
number
mean
sd
jan
feb
fifth
affili
hospit
sun
yatsen
univers
elig
patient
age
year
older
pneumonia
without
invas
noninvas
ventil
exclus
criteria
appli
stage
diagnos
realtim
reversetranscriptas
polymerasechainreact
rtpcr
assay
nasal
pharyng
swab
specimen
laboratoryconfirm
case
includ
analysi
patient
enrol
studi
diagnos
accord
world
health
organ
interim
guidanc
jan
elig
patient
offer
treatment
arbidol
lpvr
combin
group
oral
lpvr
monotherapi
group
inform
consent
obtain
patient
next
kin
treatment
protocol
approv
pharmaci
therapeut
committe
studi
approv
research
ethic
committe
fifth
affili
hospit
sun
yatsen
univers
allow
retrospect
access
patient
record
file
lunzi
nasopharyng
specimen
posit
test
rtpcr
patient
patient
abnorm
radiolog
find
oral
drug
given
strictli
manag
patient
regardless
sever
ill
care
monitor
laboratori
examin
chest
ct
scan
specif
arbidol
given
dose
mg
everi
h
lopinavir
mg
ritonavir
mg
oral
everi
h
coronaviru
detect
neg
rtpcr
tree
time
administr
period
day
patient
receiv
appropri
support
care
regular
clinic
laboratori
monitor
normal
renal
function
liver
enzym
blood
count
assess
baselin
everi
day
throughout
treatment
cours
rtpcr
perform
nasopharyng
specimen
everi
day
daili
neg
test
admiss
hospit
test
daili
stool
addit
stool
collect
patient
rtpcr
analysi
chest
ct
scan
perform
day
patient
monitor
clinic
sign
depress
acut
confus
primari
endpoint
neg
convers
rate
date
diagnosi
assess
whether
pneumonia
progress
improv
chest
ct
use
fischer
exact
test
categor
variabl
wherea
use
student
test
continu
variabl
assess
differ
mean
two
group
graphic
statist
test
suggest
proport
hazard
assumpt
violat
statist
analys
use
spss
softwar
version
spss
chicago
illinoi
signific
statist
analys
defin
p
fiftysix
individu
age
diagnos
infect
jan
feb
recent
research
report
patient
lymphopenia
thrombocytopenia
respect
overal
leukopenia
observ
patient
patient
demonstr
high
level
creactiv
protein
high
level
alanin
aminotransferas
aspart
aminotransferas
creatin
kinas
ddimer
less
common
similar
characterist
observ
patient
furthermor
found
stool
patient
posit
test
rtpcr
addit
patient
count
peripher
cell
reduc
flow
cytometr
analysi
baselin
characterist
gener
similar
patient
receiv
oral
arbidol
lpvr
therapi
receiv
oral
lpvr
tabl
except
organ
dysfunct
present
four
patient
admit
transfer
icu
ten
patient
treat
antivir
drug
data
yet
public
abnorm
radiolog
find
present
nine
patient
fig
exclud
inelig
patient
patient
includ
studi
mean
age
patient
year
sd
men
tabl
median
number
comorbid
rang
mean
blood
indic
day
diagnosi
includ
peripher
white
cell
count
l
sd
l
lymphocyt
count
l
l
platelet
l
l
bilirubin
overal
patient
need
doubl
nasal
cathet
oxygen
patient
receiv
immunoglobulin
therapi
receiv
broadspectrum
antibacteri
therapi
overal
lung
total
sever
score
reach
sum
five
lobe
score
five
lung
lobe
assess
degre
involv
classifi
none
minim
mild
moder
sever
none
correspond
lobe
score
minim
lobe
score
mild
lobe
score
moder
lobe
score
sever
lobe
score
patient
reach
lobe
score
combin
group
monotherapi
group
baselin
characterist
statist
signific
differ
two
group
tabl
howev
receiv
corticosteroid
therapi
combin
group
compar
monotherapi
group
p
tabl
statist
signific
differ
baselin
characterist
support
measur
note
two
group
tabl
treatment
day
patient
nasopharyng
specimen
neg
test
rtpcr
combin
group
compar
monotherapi
group
p
fig
day
respect
coronaviru
could
detect
p
fig
furthermor
chest
ct
scan
improv
patient
combin
group
day
compar
monotherapi
group
p
fig
howev
three
patient
monotherapi
group
still
posit
stool
test
one
combin
group
fig
signific
differ
laboratori
indic
two
group
note
treatment
period
treatment
period
patient
demonstr
elev
level
bilirubin
mean
top
bilirubin
depress
acut
confus
diagnos
patient
either
group
effect
treatment
intervent
patient
sever
still
urgent
need
patient
sar
treat
lpvr
appear
reduc
viral
load
lpvr
recommend
patient
merscov
arbidol
arbidol
mesyl
shown
direct
antivir
effect
earli
viral
replic
vitro
sarscov
impli
therapeut
window
could
exploit
provid
activ
antivir
agent
avail
fundament
strategi
treatment
coronaviru
therefor
find
effect
antivir
agent
would
decreas
peak
viral
load
thu
associ
degre
immunopatholog
damag
typic
patient
without
invas
ventil
studi
show
oral
arbidol
lpvr
combin
group
associ
signific
elev
neg
convers
rate
coronaviru
test
compar
lpvr
monotherapi
group
furthermor
combin
therapi
associ
significantli
improv
chest
ct
scan
fortun
patient
develop
acut
respiratori
failur
treatment
period
clear
whether
effect
antivir
drug
accord
suppos
reduc
viral
load
soon
possibl
could
benefit
delay
progress
lung
lesionsstool
portion
patient
posit
test
rtpcr
case
patient
monotherapi
group
test
remain
posit
stool
show
neg
respiratori
sampl
chest
ct
scan
may
better
way
assess
effect
treatment
compar
nasopharyng
specimen
test
coronaviru
prove
use
viral
receptor
entri
process
mrna
highli
express
gastrointestin
system
provid
prerequisit
infect
total
intak
dose
arbidol
excret
unchang
within
h
mainli
fece
much
less
urin
lpvr
found
unchang
stool
oral
arbidol
combin
lpvr
may
achiev
high
fecal
concentr
stop
viral
replic
site
combin
therapi
may
like
prefer
patient
stool
test
posit
physic
biochem
examin
main
organ
system
reveal
signific
differ
arbidoltr
control
group
indic
good
toler
safeti
arbidol
human
gastrointestin
symptom
diarrhea
nausea
elev
level
bilirubin
wellrecogn
complic
lpvr
therapi
note
previous
treatment
arbidol
lpvr
well
toler
studi
patient
receiv
corticosteroid
therapi
monotherapi
group
nevertheless
improv
chest
ct
scan
day
like
corticosteroid
nt
conduc
recoveri
lung
injuri
use
corticosteroid
controversi
review
although
glucocorticoid
group
younger
fewer
underli
diseas
advers
outcom
increas
risk
icu
admiss
mortal
patient
sar
receiv
hormon
therapi
glucocorticoid
could
delay
clearanc
coronaviru
nucleic
acid
without
lower
mortal
patient
merscov
infect
one
limit
studi
small
size
review
albeit
littl
signific
clinic
investig
far
assess
use
combin
treatment
patient
although
baselin
characterist
treatment
compar
group
seem
reason
balanc
substanti
differ
might
appar
small
number
patient
studi
review
also
limit
retrospect
nonrandom
natur
inevit
select
unmeasur
confound
bia
exclud
entir
could
altern
interpret
result
undoubtedli
new
intervent
ideal
assess
random
control
clinic
trial
howev
approach
gener
accept
alway
practic
feasibl
context
emerg
rel
uncommon
diseas
merscov
infect
begin
select
control
group
care
ensur
two
cohort
match
close
possibl
clinic
characterist
treatment
intervent
chest
ct
imag
receipt
arbidol
lpvr
remov
four
individu
admit
transfer
icu
organ
dysfunct
outli
baselin
serum
creatinin
compar
group
minim
risk
spuriou
conclus
driven
clinic
characterist
might
potenti
detriment
clinic
outcom
clinic
outcom
individu
mask
investig
select
patient
match
assess
measur
includ
futur
clinic
studi
explor
therapeut
benefit
antivir
intervent
patient
infect
recent
research
suggest
frequent
associ
presum
hospitalrel
transmiss
patient
requir
intens
care
unit
treatment
mortal
wuhan
china
therapeut
emphasi
therefor
antivir
earli
would
decreas
peak
viral
load
thu
associ
degre
immunopatholog
damag
would
reduc
need
immunosuppress
often
associ
increas
risk
nosocomi
infect
one
possibl
implic
arbidol
combin
lpvr
might
benefit
delay
progress
lung
lesion
lower
possibl
respiratori
gastrointestin
transmiss
decreas
viral
load
contain
high
fecal
concentr
random
prospect
studi
still
need
mechan
antivir
effect
coronaviru
remain
unclear
extern
fund
receiv
studi
author
declar
conflict
interest
